Bispecific T-cell engagers in relapsed/refractory B-cell non-Hodgkin lymphoma: mechanisms and clinical landscape.
Bispecific antibodies engaging T cells show promise for treating blood lymphomas resistant to other treatments.
This paper reviews bispecific T-cell engaging antibodies for treating relapsed/refractory B-cell non-Hodgkin lymphoma. It covers the mechanisms and evolving clinical landscape of this rapidly expanding therapeutic class.
What the study was
- Population
- Relapsed/refractory B-cell NHL patients
- Category
- Treatment Innovation
- Maturity
- Validated
Why it surfaced
Hot therapeutic area bridging immunotherapy and hematologic malignancy watchlists. Limited metadata.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.